Immune cell therapy aims to tame severe transplant complication
NCT ID NCT06920199
First seen Sep 30, 2025 · Last updated May 09, 2026 · Updated 21 times
Summary
This early-phase study tests whether immune cells from the original donor, combined with a low dose of interleukin-2, can safely treat chronic graft-versus-host disease (cGVHD) that hasn't responded to standard steroids. About 18 adults aged 18-70 who had a stem cell transplant and now have moderate to severe cGVHD will receive the treatment. The main goal is to check for dangerous side effects, while also seeing if the therapy boosts helpful immune cells and improves symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, 200080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.